Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma

not yet the standard of care

Research output: Contribution to journalLetterOtherpeer-review

Original languageEnglish
Pages (from-to)e119
Number of pages1
JournalThe Lancet Haematology
Volume6
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019

Cite this

@article{f95e4290d9364a01a2b895b3ec011d7c,
title = "Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care",
author = "Casan, {Joshua ML} and Alison Barraclough and Jake Shortt and Hawkes, {Eliza A.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/S2352-3026(19)30013-4",
language = "English",
volume = "6",
pages = "e119",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Elsevier",
number = "3",

}

Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma : not yet the standard of care. / Casan, Joshua ML; Barraclough, Alison; Shortt, Jake; Hawkes, Eliza A.

In: The Lancet Haematology, Vol. 6, No. 3, 01.03.2019, p. e119.

Research output: Contribution to journalLetterOtherpeer-review

TY - JOUR

T1 - Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma

T2 - not yet the standard of care

AU - Casan, Joshua ML

AU - Barraclough, Alison

AU - Shortt, Jake

AU - Hawkes, Eliza A.

PY - 2019/3/1

Y1 - 2019/3/1

UR - http://www.scopus.com/inward/record.url?scp=85061927815&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(19)30013-4

DO - 10.1016/S2352-3026(19)30013-4

M3 - Letter

VL - 6

SP - e119

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

IS - 3

ER -